Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314914 | 0.84 | SCN5A (0.40) | SCN5AGRIN2BTLR7PSDSCN1A | |
| SCHEMBL22314208 | 0.83 | SCN5A (0.41) | TP53SCN5AGRIN2BPSDSCN1A | |
| SCHEMBL22314912 | 0.83 | SCN5A (0.52) | TP53SCN5AGRIN2BPSDSCN1A | |
| SCHEMBL25865160 | 0.83 | SCN5A (0.41) | TP53SCN5AGRIN2BPSDSCN1A | |
| SCHEMBL22314514 | 0.82 | SCN5A (0.45) | SCN5AGRIN2BPSDNOTUM | |
| SCHEMBL25865147 | 0.82 | PDE5A (0.42) | SCN5AGRIN2BSCN1ASCN2ATNIK | |
| SCHEMBL25865032 | 0.81 | SCN5A (0.44) | SCN5AGRIN2BPSDTNIKNOTUM | |
| SCHEMBL22314548 | 0.81 | SCN5A (0.43) | SCN5AGRIN2BPSDTNIKNOTUM | |
| SCHEMBL22314994 | 0.81 | SCN5A (0.38) | SCN5AGRIN2BTNIK | |
| SCHEMBL22314918 | 0.81 | SCN5A (0.52) | SCN5AGRIN2BPSDSCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | TP53 4487/4885SCN5A 8/4885GRIN2B 120/4885 |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | TP53 4487/4885SCN5A 8/4885GRIN2B 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.